Menu Search
Equities

IGC Pharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IGS1:FRA

IGC Pharma Inc

Actions
  • Price (EUR)0.21
  • Today's Change0.00 / 0.00%
  • Shares traded82.01k
  • 1 Year change-27.59%
  • Beta0.3249
Data delayed at least 15 minutes, as of Feb 18 2026 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year IGC Pharma Inc had revenues fall -5.50% from 1.35m to 1.27m, though the company grew net income from a loss of 13.00m to a smaller loss of 7.12m.
Gross margin46.20%
Net profit margin-582.82%
Operating margin-731.83%
Return on assets-64.10%
Return on equity-83.34%
Return on investment-81.62%
More ▼

Cash flow in USDView more

In 2025, cash reserves at IGC Pharma Inc fell by 793.00k. Cash Flow from Financing totalled 4.45m or 350.20% of revenues. In addition the company used 4.80m for operations while cash used for investing totalled 442.00k.
Cash flow per share-0.0712
Price/Cash flow per share--
Book value per share0.088
Tangible book value per share0.0349
More ▼

Balance sheet in USDView more

IGC Pharma Inc uses little debt in its capital structure as supported by a debt to capital ratio of 1.65%.
Current ratio1.32
Quick ratio0.889
Total debt/total equity0.0168
Total debt/total capital0.0165
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.